Sickle cell nephropathy (SCN) is a poorly studied complication of pediatric patients. It appears in different forms, including glomerulopathy, and tubulopathies. Objective: To describe acute and chronic renal complications in patients with sickle cell anemia (SCA). Patients and Method: Retrospective study. Pediatric patients with confirmed diagnosis of sickle cell disease were included who had a nephro-urology study. Hemoglobin electrophoresis pattern, presence and type of renal involvement, and presence of cardiac involvement were recorded. Bivariate analysis was performed to compare patients with and without SCN. Results: 79 patients were included, 59.5% of them were men, and the most frequent electrophoresis pattern was Hb-SS (60.9%). The SCN occurred in 70% of patients with an average age of 114 months (RIQ 65-157). The most frequently observed alterations were glomerular hyperfiltration, microalbuminuria, acute kidney injury, arterial hypertension, and hyposthenuria. In the bivariate analysis, an abnormal echocardiogram result was presented more frequently in patients with SCN (84.8% vs. 54.3% p = 0.01), as well as more frequent use of nephrotoxic drugs (74.5% vs. 54.2% p = 0.07). Conclusions: Our findings suggest that sickle cell nephropathy may occur at an early age, where glomerular hyperfiltration is very common. Cardiopulmonary complications in patients with SCA may be related to the presence of SCN.
[corrected] Nephrotic syndrome is one of the most frequent glomerular diseases among children, and steroid therapy remains as the treatment choice. In spite of this, 10 to 15% of the patients are steroidresistant, and the best therapy for such cases has never been defined. Mycophenolate acid (MA) is one of the treatments used in such situations.
Objectives. Atypical hemolytic uremic syndrome (aHUS) is a rare complement-mediated kidney disease with genetic predisposition and represents up to 10% of pediatric hemolytic uremic syndrome (HUS) cases. Few studies have evaluated aHUS in Latin American population. We studied a Colombian pediatric cohort to delineate disease presentation and outcomes. Methods. A multicenter cohort of 27 Colombian children with aHUS were included. Patients were grouped by age at onset. Clinical features were compared using analysis of variance (ANOVA) and Fisher exact tests. Renal biopsy was performed on 6 patients who were suspected of having other renal diseases before aHUS diagnosis. Results. Most patients were male (70%). The onset of aHUS occurred frequently before age 4 years (60%) and followed gastroenteritis as the main triggering event (52%). Age groups showed comparable clinical presentation, disease severity, treatment, and outcomes. Pulmonary involvement (67%) was the main extrarenal manifestation, particularly in the 1 to 7 age group ( P = .01). Renal biopsies were as follows: 3 had membranoproliferative glomerulonephritis (MPGN) type I, one MPGN type III, one C3-glomerulonephritis, and one rapidly progressive GN. Genetic screening was available in 6 patients and identified 2x CFHR5, 2xMCP, 1x ADAMTS13/THBD, and 1x DGKE mutations. A total of 15 relapses were seen, of which 8 (72%) occurred in the 1 to 7 age group. The renal outcome was not significantly different regardless of age group. Conclusion. In our cohort, we observed a relatively high frequency of extrarenal involvement at first presentation represented by pulmonary manifestations. The renal prognosis at initial presentation was worse than in previous reports.
La vejiga neurogénica es una patología con riesgo de daño renal. La Asociación Colombiana de Nefrología Pediátrica (ACONEPE) en colaboración con especialistas en urología pediátrica, cirugía pediátrica, nefrología pediátrica y fisioterapeutas de piso pélvico diseñamos una guía de práctica clínica para el diagnóstico, tratamiento y seguimiento de pacientes menores de 18 años con vejiga neurogénica. Objetivo: Generar pautas que permitan unificar la práctica clínica de los profesionales para la atención de pacientes portadores de vejiga neurogénica, con el fin de disminuir las complicaciones asociadas y la progresión a enfermedad renal crónica. Material y Método: Se realizó una búsqueda sistemática de la literatura, y se analizaron las recomendaciones de guías con calificación superior al 60% según la herramienta AGREE II. Se realizaron búsquedas complementarias en caso de preguntas que requirieron información adicional. Las recomendaciones fueron graduadas según el sistema GRADE o según graduación original. Las recomendaciones finales se acordaron mediante consenso de expertos con umbral de acuerdo del 80%. Resultados: La búsqueda inicial arrojó 75 documentos, de los cuales se incluyeron 8 guías de práctica clínica publicadas entre 2012 y 2020, en el análisis inicial. Dos documentos no cumplieron el dominio de rigor metodológico y uno no cumplió con los criterios de independencia editorial. Al final se incluyeron 5 guías. Conclusión: Se elaboran recomendaciones orientadas a la estandarización de la práctica clínica de los profesionales involucrados en la atención de pacientes con vejiga neurogénica. Estas recomendaciones son aplicables en todos los países de Latinoamérica. En esta segunda parte se realizan recomendaciones respecto al tratamiento de pacientes pediátricos con vejiga neurogénica.
La vejiga neurogénica es una condición con riesgo de daño renal. Su diagnóstico y manejo oportuno mejora el pronóstico renal de los pacientes pediátricos. Como una iniciativa de la Asociación Colombiana de Nefrología Pediátrica (ACONEPE), y con la colaboración de especialistas en urología pediátrica, cirugía pediátrica, nefrología pediátrica y fisioterapeutas del piso pélvico de Latinoamérica, se diseñó una guía de práctica clínica para el diagnóstico, tratamiento y seguimiento de pacientes menores de 18 años con vejiga neurogénica. Objetivo: Generar pautas que permitan unificar la práctica clínica de los profesionales para la atención de pacientes portadores de vejiga neurogénica, con el fin de disminuir las complicaciones asociadas y la progresión a enfermedad renal crónica. Material y Método: Se analizaron las guías disponibles en la literatura con calificación superior a 60% en los dominios de rigor metodológico e independencia editorial según la herramienta AGREE II. Para preguntas que ameritaron información adicional, se realizaron búsquedas complementarias. Las recomendaciones fueron graduadas con el sistema GRADE. Para las recomendaciones extraídas de otras guías se mantuvo la gradación del grupo desarrollador original. Se realizó un consenso de expertos, con umbral de acuerdo del 80%, para definir las recomendaciones finales. Resultados: La búsqueda inicial arrojó 75 documentos, de los cuales se incluyeron 8 guías de práctica clínica publicadas entre 2012 y 2020 en el análisis inicial. Dos documentos no cumplieron el dominio de rigor metodológico y uno no cumplió con los criterios de independencia editorial. Al final se incluyeron 5 guías. Conclusión: Se generaron recomendaciones que permiten unificar la práctica clínica de los profesionales involucrados en la atención de pacientes con vejiga neurogénica. Estas recomendaciones son aplicables en todos los países de Latinoamérica. En esta primera parte se presentan las recomendaciones de diagnóstico y seguimiento.
Introduction: Steroid-resistant nephrotic syndrome (SRNS) represents a severe and challenging form of pediatric nephrotic syndrome and is associated with a high risk of progression to end-stage kidney disease. Calcineurin inhibitors (CNIs) are the standard second-line therapy; however, their use is limited by frequent relapses and long-term nephrotoxicity. Mycophenolate mofetil (MMF) offers a more favorable safety profile and a complementary mechanism of action; however, the clinical utility of combining MMF with CNIs remains largely under-explored in this population. Case Presentation: We describe a series of nine pediatric patients with steroid-resistant or steroid-dependent nephrotic syndrome who were refractory to cyclosporine monotherapy. These patients were treated with a combination regimen of cyclosporine (4–5 mg/kg/day; target trough levels of 75–150 ng/mL) and MMF (600 mg/m2/day). This therapeutic approach was associated with a reduction in corticosteroid dosage and a decrease in the annual number of relapses in most patients. Conclusions: In this small case series of pediatric patients with corticosteroid-dependent or steroid-resistant nephrotic syndrome refractory to cyclosporine monotherapy, the addition of mycophenolate mofetil was associated with a reduction in relapse frequency and corticosteroid requirements. Despite the limited sample size, these findings suggest that combination therapy may be a therapeutic option in difficult-to-treat pediatric nephrotic syndrome and warrant further evaluation in controlled studies.